减低剂量阿扎胞苷治疗中高危MDS及MDS/MPN患者的临床疗效

目的 观察减低剂量阿扎胞苷治疗中高危骨髓增生异常综合征(MDS)及骨髓增生异常综合征/骨髓增殖性肿瘤(MDS/MPN)患者的临床疗效.方法 选取2018年12月至2021年1月安徽医科大学第一附属医院收治中高危MDS(24例)及MDS/MPN(13例)患者,采取减低剂量阿扎胞苷[60 mg/(m2·d),连续7 d,2...

The clinical efficacy of reduced-dose azacitidine in patients with intermediate and high risk myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms

Objective To observe the clinical efficacy of reduced-dose azacitidine on patients with intermediate and high risk myelodysplastic syndrome (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms(MDS/MPN). Methods Twenty-four patients with MDS and thirteen patients with MDS/MPN from the First Affiliated Hospital of Anhui Medical University between December 2018 and January 2021 were treated with reduced-dose azacitidine[60 mg/(m²·d) for 7 days per 28-day cycle], then the clinical efficacy and adverse effects were analyzed. Results The median number of cycles was two. Next-generation gene sequence was performed among 32 patients, and mutations in genes were identified in 27 patients (84.38%). 54.05% of patients responded to the reduced-dose azacitidine. Patients who received at least three cycles had a better response to azacitidine than those who received fewer than three cycles (80.00% vs 36.36%, P=0.018). The median survival was 15.00 months in the follow-up period. Adverse effects included myelosuppression, infection, and gastrointestinal reaction. Conclusions Reduced-dose azacitidine is effective and safe for patients with intermediate risk or high risk MDS and MDS/MPN, and the clinical efficacy is better in patients who have received multiple cycles.